STOCK TITAN

Immutep Limited - IMMP STOCK NEWS

Welcome to our dedicated news page for Immutep (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immutep's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immutep's position in the market.

News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.68%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
clinical trial
Immutep Limited

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

303.05M
1.06B
0.01%
2.74%
0.91%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Sydney

About IMMP

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.